Empagliflozin治疗糖尿病的研究进展

Developments in the Research of the Treatment of Diabetes with Empagliflozin

钠葡萄糖协同转运蛋白2(SGLT2)抑制剂是近年来降糖药研究的新热点,其通过抑制肾小管上皮细胞内的主要血糖转运蛋白SGLT2,降低肾小管对葡萄糖的重吸收,从而降低血浆内葡萄糖。临床试验表明新型SGLT2抑制剂Empagliflozin具有良好的降糖效果,能显著降低空腹血糖(FPG)、糖化血红蛋白(HbA1c),还能显著降低血压和体重,有较好的临床应用前景。

Sodium glucose-assisted SGLT2 inhibitor is a new hot spot of research on anti-diabetic drugs in recent years. Through suppressing SGLT2, the main blood glucose transporter in the epithelial cells of kidney tubules and hence reducing the re-absorption of glucose by kidney tubules, it serves to lower the amount of glucose inside blood serum. Clinical tests have shown that Empagliflozin, as a new type of SGLT2 inhibitor, has a rather good effect on lowering the blood glucose level, and is able to induce a marked decrease of FPG and HbAlc, as well as one＇s blood pressure and body weight and is exoected to have a bright prosoect for clinical application